Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMMX Immix Biopharma, Inc.

Trading 07-01 15:26:31 EDT

9.76

-0.55

-5.33%

High10.29	Low9.60	Vol1.18M
Open10.15	D1 Closing10.31	Amplitude6.64%
Mkt Cap694.81M	Tradable Cap554.18M	Total Shares71.19M
T/O11.64M	T/O Rate2.08%	Tradable Shares56.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":9.76,"timestamp":1782933988510,"preClose":10.31,"halted":0,"volume":1179757,"delay":0,"changeRate":-0.05334626576139677,"floatShares":56781100,"shares":71190000,"eps":-0.888277,"marketStatus":"Trading","change":-0.55,"latestTime":"07-01 15:26:31 EDT","open":10.15,"high":10.285,"low":9.6,"amount":11636239.410007,"amplitude":0.06644,"askPrice":9.78,"askSize":700,"bidPrice":9.76,"bidSize":404,"shortable":3,"etf":0,"ttmEps":-0.888277,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1782936000000},"marketStatusCode":2,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":10.31,"preHourTrading":{"tag":"盘前","latestPrice":10.13,"preClose":10.31,"latestTime":"09:29 EDT","volume":1521,"amount":15745.294656,"timestamp":1782912598991,"change":-0.18,"changeRate":-0.017459,"amplitude":0.106693},"postHourTrading":{"tag":"盘后","latestPrice":10.31,"preClose":10.31,"latestTime":"19:56 EDT","volume":9916,"amount":102211.7426,"timestamp":1782863782908,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.440167,"impliedVol":1.2129,"impliedVolPercentile":0.4821},"requestUrl":"/m/hq/s/IMMX/wiki","defaultTab":"wiki","newsList":[{"id":"2644089202","title":"Immix Biopharma Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $27","url":"https://stock-news.laohu8.com/highlight/detail?id=2644089202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644089202?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:51","pubTimestamp":1781790680,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644880650","title":"BofA Initiates Immix Biopharma at Buy With $27 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2644880650","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644880650?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:55","pubTimestamp":1781783717,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) has an average rating of buy and mean price target of $19.79, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644872525","title":"Immix Biopharma Initiated at Outperform by LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2644872525","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644872525?lang=en_us&edition=fundamental","pubTime":"2026-06-18 02:48","pubTimestamp":1781722080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 14:48 ET (18:48 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644728162","title":"Immix Biopharma publishes corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644728162","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644728162?lang=en_us&edition=fundamental","pubTime":"2026-06-18 01:09","pubTimestamp":1781716143,"startTime":"0","endTime":"0","summary":"Immix outlined its NXC-201 BCMA-targeted CAR-T program for relapsed or refractory AL amyloidosis, highlighting a lack of FDA-approved therapies in this setting.Company materials cited a 95% complete response rate for NXC-201 in NEXICART-2, versus 0-10% for current investigator’s-choice regimens.Regulatory positioning highlighted FDA Breakthrough Therapy Designation in January 2026, RMAT in February 2025, Orphan Drug Designation in September 2023.Development timeline showed NEXICART-2 enrollment completion at 45 patients in March 2026, with the next update slated for late September 2026.Planned BLA submission targeted 1H 2027, with a commercial launch plan tied to approval in 1H 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL5VKvJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639670899","title":"Immix Biopharma shareholders elect directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639670899","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639670899?lang=en_us&edition=fundamental","pubTime":"2026-05-30 05:10","pubTimestamp":1780089052,"startTime":"0","endTime":"0","summary":"Immix Biopharma held its annual shareholder meeting on May 22, 2026.Shareholders selected the company’s director nominees to serve until the next annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLbX29jW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638529111","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638529111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638529111?lang=en_us&edition=fundamental","pubTime":"2026-05-27 07:50","pubTimestamp":1779839409,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX). Biohaven Ltd. (B...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-biohaven-ltd-bhvn-and-immix-biopharma-immx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-biohaven-ltd-bhvn-and-immix-biopharma-immx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU1093756325.SGD","BK4137","BK4581","BHVN","LABU","LU0029874061.USD","IMMX","LU0128526141.USD","XBI","BK4588","HCSG","LU1093756168.USD","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334267","title":"Immix Biopharma closes $150 million common stock offering at $8.94 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334267","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637334267?lang=en_us&edition=fundamental","pubTime":"2026-05-23 05:15","pubTimestamp":1779484526,"startTime":"0","endTime":"0","summary":"Immix Biopharma closed an underwritten follow-on offering of 16,778,524 common shares priced at USD 8.94 each.Net proceeds totaled about USD 140.65 million, reflecting underwriting discounts, commissions, and offering expenses.Morgan Stanley led the deal, with BofA Securities as book-runner.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLbSWC1t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1280957306.USD","LU0158827781.USD","LU0211331839.USD","LU2111349929.HKD","LU0203347892.USD","LU2210149790.SGD","LU0225283273.USD","LU1989772923.USD","LU1366192091.USD","LU1791710582.SGD","BAC","LU0640476718.USD","LU0210528500.USD","NDAQ","LU0070302665.USD","LU0477156797.USD","LU1244550494.USD","BK4207","LU0390134368.USD","IE00BN0W2T93.GBP","LU1244550221.USD","IE00BZ1G4Q59.USD","LU1074936037.SGD","LU1363072403.SGD","LU0158827948.USD","LU1506573853.SGD","LU1064131342.USD","LU0795875169.SGD","LU2357305700.SGD","LU1880398471.USD","LU0130518102.USD","SG9999014039.USD","LU1989772840.SGD","LU2133065610.SGD","LU1791710400.SGD","LU0098860793.USD","LU0053666078.USD","LU0130102774.USD","LU0052756011.USD","LU0648000940.SGD","LU0314106906.USD","LU2023251221.USD","IMMX","BK4581","LU1894683348.USD","LU2095319765.USD","LU1720051108.HKD","LU0130103400.USD","LU0306807586.USD","LU0234572021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637034264","title":"Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2637034264","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637034264?lang=en_us&edition=fundamental","pubTime":"2026-05-23 05:15","pubTimestamp":1779484500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUA4LXN12:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637734564","title":"Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2637734564","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637734564?lang=en_us&edition=fundamental","pubTime":"2026-05-23 00:14","pubTimestamp":1779466440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 22, 2026 12:14 ET (16:14 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637348382","title":"Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $20 From $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2637348382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637348382?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:38","pubTimestamp":1779460716,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nAZN4SXXPA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637438094","title":"Immix Biopharma Prices $150 Million Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2637438094","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637438094?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:06","pubTimestamp":1779361568,"startTime":"0","endTime":"0","summary":"Immix Biopharma  priced an underwritten public offering of 16.8 million shares of common stock at $8.94 per share, raising expected gross proceeds of about $150 million, the company said Thursday.Proceeds from the offering will fund NXC-201 development, working capital, and general corporate purposes, and together with existing cash, support operations into mid-2028, the company said.The offering is expected to close Friday, the company added.Immix Biopharma shares were up 9.7% in premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637824403","title":"Immix Biopharma prices USD 150 million follow-on stock offering at USD 8.94/share","url":"https://stock-news.laohu8.com/highlight/detail?id=2637824403","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637824403?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:30","pubTimestamp":1779359419,"startTime":"0","endTime":"0","summary":"Immix Biopharma priced an underwritten follow-on offering of 16,778,524 common shares at USD 8.94 each, targeting USD 150 million in gross proceeds.Closing is expected around May 22, 2026, subject to customary conditions.Net proceeds are earmarked for NXC-201 development, working capital, general corporate purposes; cash runway projected into mid-2028.Morgan Stanley is lead book-runner; BofA Securities is also a book-running manager.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL5pNF2J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","LU1894683348.USD","LU1363072403.SGD","LU0683600562.USD","LU0477156953.USD","LU0225283273.USD","LU1506573853.SGD","LU0052756011.USD","LU1548497426.USD","NDAQ","LU1035773651.USD","BK4534","BK4581","BAC","LU0868494617.USD","LU0912757837.SGD","LU1718418525.SGD","LU0306807586.USD","LU1894683264.USD","LU0070302665.USD","LU0321505439.SGD","LU1791710400.SGD","LU0098860793.USD","IE00B3QW5Z07.USD","IE00BLSP4239.USD","LU2264538146.SGD","LU0971096721.USD","LU1162221912.USD","LU1069347547.HKD","LU1880398471.USD","LU0158827948.USD","IE00BGHQF748.EUR","LU0158827781.USD","IE00BLSP4452.SGD","IE00B64PRP62.GBP","LU1791807156.HKD","LU0648000940.SGD","IE0034235188.USD","LU1883839398.USD","IE00B19Z3581.USD","LU1791710582.SGD","LU0208291251.USD","IMMX","LU2111349929.HKD","LU1280957306.USD","LU0170899867.USD","LU2089284900.SGD","SG9999014021.USD","LU0980610538.SGD","LU0130518102.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637822333","title":"Immix Biopharma Inc: Pricing of Offering of 16.8 Mln Shares at Price to Public of $8.94 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2637822333","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637822333?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:30","pubTimestamp":1779359409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0HM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637481382","title":"Immix Biopharma Inc - Net Proceeds to Fund Nxc-201 Development, Working Capital, and Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2637481382","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637481382?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:30","pubTimestamp":1779359400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA82WD8X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637382482","title":"Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2637382482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637382482?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:30","pubTimestamp":1779359400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA82WD8X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637848773","title":"Immix Biopharma Inc - No Relapses Observed to-Date for Patients Who Have Reached Complete Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2637848773","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637848773?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:02","pubTimestamp":1779357763,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0H8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637838482","title":"Immix Biopharma Inc - All Four Mrd-Negative Patients Convert to Complete Response in Nexicart-2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2637838482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637838482?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:02","pubTimestamp":1779357763,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637384825","title":"Immix Biopharma Inc - All Complete Responses Reached Within 1 Year of Follow-up Post-Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2637384825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637384825?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:02","pubTimestamp":1779357763,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0H8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637738100","title":"Immix Biopharma says NEXICART-2 trial posts 95% complete response rate in AL amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2637738100","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637738100?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:01","pubTimestamp":1779357688,"startTime":"0","endTime":"0","summary":"Immix Biopharma reported an interim update from its NEXICART-2 trial in relapsed or refractory AL amyloidosis, showing most treated patients achieved a complete response with no relapses seen so far among those responders.Results for a subset of patients had already been presented at ASH 2025, with those patients now having converted to complete response in the latest follow-up.Management framed the data as support for starting a multi-center, randomized Phase 3 trial in newly diagnosed patients.The next NEXICART-2 update is expected in late September 2026, with 1-year follow-up data targeted by end of March 2027 to support a planned BLA submission and commercial launch.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL1g0z3z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014039.USD","LU0314104364.USD","LU2095319765.USD","BK4112","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4139","NDAQ","BK4585","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637814503","title":"Immix Biopharma Announces 95% Complete Response Rate in Interim Update From Relapsed/Refractory Al Amyloidosis Clinical Trial Nexicart-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2637814503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637814503?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:00","pubTimestamp":1779357600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA6B5BBV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":0.0404},{"period":"1month","weight":0.1456},{"period":"3month","weight":0.1961},{"period":"6month","weight":0.9713},{"period":"1year","weight":3.9807},{"period":"ytd","weight":0.9713}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":-0.0128},{"period":"3month","weight":0.1397},{"period":"6month","weight":0.0951},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035123},{"month":2,"riseRate":0.2,"avgChangeRate":-0.05746},{"month":3,"riseRate":0.2,"avgChangeRate":-0.065433},{"month":4,"riseRate":0.4,"avgChangeRate":-0.025442},{"month":5,"riseRate":0.6,"avgChangeRate":0.091547},{"month":6,"riseRate":0.6,"avgChangeRate":0.103039},{"month":7,"riseRate":0.5,"avgChangeRate":0.015932},{"month":8,"riseRate":0.25,"avgChangeRate":-0.104667},{"month":9,"riseRate":0.25,"avgChangeRate":0.017421},{"month":10,"riseRate":0.75,"avgChangeRate":0.171445},{"month":11,"riseRate":1,"avgChangeRate":0.264693},{"month":12,"riseRate":1,"avgChangeRate":0.380003}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc.","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immix Biopharma, Inc.,IMMX,Immix Biopharma, Inc.股票,Immix Biopharma, Inc.股票老虎,Immix Biopharma, Inc.股票老虎国际,Immix Biopharma, Inc.行情,Immix Biopharma, Inc.股票行情,Immix Biopharma, Inc.股价,Immix Biopharma, Inc.股市,Immix Biopharma, Inc.股票价格,Immix Biopharma, Inc.股票交易,Immix Biopharma, Inc.股票购买,Immix Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}